306 related articles for article (PubMed ID: 19842933)
21. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.
Jorge AA; Arnhold IJ
Horm Res; 2009 Apr; 71 Suppl 2():55-63. PubMed ID: 19407498
[TBL] [Abstract][Full Text] [Related]
22. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor.
Blum WF; Machinis K; Shavrikova EP; Keller A; Stobbe H; Pfaeffle RW; Amselem S
J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057
[TBL] [Abstract][Full Text] [Related]
23. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
24. GH deficiency status combined with GH receptor polymorphism affects response to GH in children.
Valsesia A; Chatelain P; Stevens A; Peterkova VA; Belgorosky A; Maghnie M; Antoniazzi F; Koledova E; Wojcik J; Farmer P; Destenaves B; Clayton P;
Eur J Endocrinol; 2015 Dec; 173(6):777-89. PubMed ID: 26340968
[TBL] [Abstract][Full Text] [Related]
25. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA.
Audí L; Esteban C; Carrascosa A; Espadero R; Pérez-Arroyo A; Arjona R; Clemente M; Wollmann H; Fryklund L; Parodi LA;
J Clin Endocrinol Metab; 2006 Dec; 91(12):5038-43. PubMed ID: 17003087
[TBL] [Abstract][Full Text] [Related]
26. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults.
Meyer S; Haist M; Schaefer S; Ivan D; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Habbe N; Kann PH
Pharmacogenomics; 2008 Aug; 9(8):1017-26. PubMed ID: 18681778
[TBL] [Abstract][Full Text] [Related]
27. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
Meyer S; Ipek M; Keth A; Minnemann T; von Mach MA; Weise A; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Kann PH; ;
Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
[TBL] [Abstract][Full Text] [Related]
28. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
29. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency.
Räz B; Janner M; Petkovic V; Lochmatter D; Eblé A; Dattani MT; Hindmarsh PC; Flück CE; Mullis PE
J Clin Endocrinol Metab; 2008 Mar; 93(3):974-80. PubMed ID: 18029459
[TBL] [Abstract][Full Text] [Related]
30. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
Andujar-Plata P; Fernandez-Rodriguez E; Quinteiro C; Casanueva FF; Bernabeu I
Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993
[TBL] [Abstract][Full Text] [Related]
31. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
Hellgren G; Glad CA; Jonsson B; Johannsson G; Albertsson-Wikland K
Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
[TBL] [Abstract][Full Text] [Related]
32. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
33. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland.
Szmit-Domagalska J; Petriczko E; Drozdzynska M; Adler G; Horodnicka-Jozwa A; Ciechanowicz A; Walczak M
Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044
[TBL] [Abstract][Full Text] [Related]
34. The distribution of exon 3-deleted/full-length growth hormone receptor polymorphism in the Turkish population.
Baş F; Keleşoğlu F; Timirci Ö; Kabataş Eryılmaz S; Bozkurt N; Küçükemre Aydın B; Bundak R; Isbir T; Darendeliler F
J Clin Res Pediatr Endocrinol; 2011; 3(3):126-31. PubMed ID: 21911325
[TBL] [Abstract][Full Text] [Related]
35. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults.
Moyes VJ; Walker DM; Owusu-Antwi S; Maher KT; Metherell L; Akker SA; Monson JP; Clark AJ; Drake WM
Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of the influencing factors of recombinant human growth hormone effect in the children with Turner syndrome].
Li J; Wu W; Liang Y; Luo XP
Zhonghua Er Ke Za Zhi; 2018 Nov; 56(11):866-870. PubMed ID: 30392213
[No Abstract] [Full Text] [Related]
37. Relationship between nocturnal growth hormone concentrations, serum IGF-I/IGFBP-3 levels, insulin sensitivity and GH receptor allelic variant in small for gestational age children.
Mericq V; Román R; Iñiguez G; Angel B; Salazar T; Avila A; Perez-Bravo F; Cassorla F
Horm Res; 2007; 68(3):132-8. PubMed ID: 17347571
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
39. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
van der Klaauw AA; van der Straaten T; Baak-Pablo R; Biermasz NR; Guchelaar HJ; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980
[TBL] [Abstract][Full Text] [Related]
40. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
